Order byBest matchMost fresh
Why Sarepta Therapeutics (SRPT) Stock Is Down Today
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 44.4% in the afternoon session after the company reported a second death linked to its Duchenne muscular dystrophy gene therapy. Elevidys.
These Stocks Moved the Most Today: Sarepta, AMD, Tesla, U.S. Steel, Roku, Sage Therapeutics, and More
Stocks were rising Monday after The Wall Street Journal reported Tehran was looking to resume talks with the White House over its nuclear program in order to de-escalate a military conflict with Israel.
Sarepta Therapeutics' Elevidys Liver Deaths Trigger Selloff, A Contrarian Opportunity
Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an analysis of SRPT stock now.
STAT10h
After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry
Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other parents still push for the therapy.
Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy
Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause.
Explore more
Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Bottom
Despite setbacks, Sarepta’s gene therapy pipeline and market leadership in DMD present a high-risk, high-reward setup. Read more on SRPT stock here.
Feedback